Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Conditions
Recurrent Acute Lymphoblastic Leukemia · Recurrent B Acute Lymphoblastic Leukemia · Recurrent B-Cell Prolymphocytic Leukemia · Recurrent Chronic Lymphocytic Leukemia · Recurrent High Grade B-Cell Lymphoma · Recurrent Indolent Non-Hodgkin Lymphoma · Recurrent Non-Hodgkin Lymphoma · Recurrent Transformed Chronic Lymphocytic Leukemia · Refractory Acute Lymphoblastic Leukemia · Refractory B Acute Lymphoblastic Leukemia · Refractory B-Cell Prolymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia · Refractory High Grade B-Cell Lymphoma · Refractory Indolent Non-Hodgkin Lymphoma · Refractory Non-Hodgkin Lymphoma · Refractory Transformed Chronic Lymphocytic Leukemia · Refactory Childhood Acute Lymphoblastic Leukemia · Refractory Childhood Non-Hodgkin Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Nationwide Children's Hospital, Columbus, Ohio, United States
Contact: Study coordinator (Kennedy Thompson) · Kennedy.thompson@nationwidechildrens.org · 614-722-5043Contact: Principal Investigator (Margaret Lamb, MD)Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (Sumithira Vasu, MD)
Study leads
Sumithira Vasu, MD
Principal Investigator
Ohio State University Comprehensive Cancer Center